Wernli M, Gratwohl A, von Fliedner V, Tichelli A, Clément F, Grob J P, Chapuis B, Maurice P, Brun del Re G, Fey M F
Departement Innere Medizin, Kantonsspital, Basel.
Schweiz Med Wochenschr. 1991 Feb 9;121(6):194-8.
Acute lymphoblastic leukemia (ALL) is conventionally treated in three phases: remission induction, consolidation and maintenance. In adults initial remission rates of nearly 80% can be achieved. The 3 to 5 year leukemia free survival is 20 to 40%. Most relapses occur during maintenance, despite continuous therapy for 2 to 3 years. The value of maintenance therapy following intensive induction in adults is not documented. In this pilot study we treated 34 patients with ALL in five Swiss centers between 1986 and 1989 with intensive induction/consolidation therapy alone. Three induction/consolidation courses were applied: course I, 43 days, consisting of daunomycin, vincristine, prednisone, methotrexate, L-asparaginase and intrathecal CNS prophylaxis; course II, 6 days, consisting of high dose cytosine arabinoside and VP-16; course III, three non randomized arms, either allogeneic or autologous bone marrow transplantation (BMT) or high dose cyclophosphamide and repeated intrathecal therapy alone. 32 patients (94%) reached complete remission (CR): 24 after course I (71%), 7 after course II (cumulative 91%) and one after course III only (cumulative 94%). 3 patients had early, relapses before course III, 3 died of infection, and 2 of graft-versus-host disease. One patient had refractory leukemia in all three courses. 26 patients (76%) were in CR after completion of therapy. 16 relapsed within 1 to 17 months (median 5). 10 patients are free of disease after 10 to 44 months (median 24): 5 had had allogeneic BMT, 3 autologous BMT and 2 cyclophosphamide in course III.(ABSTRACT TRUNCATED AT 250 WORDS)
急性淋巴细胞白血病(ALL)传统上分为三个治疗阶段:缓解诱导、巩固和维持。在成人中,初始缓解率可达近80%。3至5年无白血病生存率为20%至40%。尽管持续治疗2至3年,但大多数复发发生在维持阶段。成人强化诱导后维持治疗的价值尚无文献记载。在这项前瞻性研究中,1986年至1989年间,我们在瑞士的五个中心对34例ALL患者仅采用强化诱导/巩固治疗。应用了三个诱导/巩固疗程:疗程I,43天,由柔红霉素、长春新碱、泼尼松、甲氨蝶呤、L-天冬酰胺酶和鞘内中枢神经系统预防组成;疗程II,6天,由大剂量阿糖胞苷和VP-16组成;疗程III,三个非随机分组,分别为异基因或自体骨髓移植(BMT)或仅采用大剂量环磷酰胺和重复鞘内治疗。32例患者(94%)达到完全缓解(CR):疗程I后24例(71%),疗程II后7例(累计91%),仅疗程III后1例(累计94%)。3例患者在疗程III前早期复发,3例死于感染,2例死于移植物抗宿主病。1例患者在所有三个疗程中均为难治性白血病。26例患者(76%)在治疗结束后处于CR状态。16例在1至17个月内复发(中位时间5个月)。10例患者在10至44个月(中位时间24个月)后无病生存:5例接受了异基因BMT,3例接受了自体BMT,2例在疗程III中接受了环磷酰胺治疗。(摘要截短至250字)